In April 1999, Tredegar - having been an early investor in Therics - announced that it had acquired that part of Therics Inc (for $13.4 million) that it did not already own. Fairly active inthe SBIR space the year previously, Therics had been developing a new microfabrication technology that had potential application in drug delivery and a variety of other medical markets. Other products offered by the SBIR-involved firm included TheraDrug(tm), an intraocular implant product to deliver pharmaceuticals on a time release basis; Theriffold(tm), tissue healing scaffolds for accelerated cellular growth; BoneGauze(tm) bone graft substitute; and the oral pharmaceutical Diclofenac(tm) --a time delayed arthritis pain relieving product. In August 2008, Therics was acquired by Integral LifeSciences - which firm has had an fairly aggressive acquisition policy involving several other SBIR-involved small firm
